Advances in Urban Resilience and Sustainable City Design

Sensor Fusion: Unleashing the Potential of Microfluidics in Next-Generation Drug Screening Platforms

Xian Zhang
Department of Biochemical Engineering, Yunnan Agricultural University, China
xian.zhang@ynau.edu.cn

Mei Chen
Department of Analytical Chemistry, Guizhou Normal University, China
mei.chen@gznu.edu.cn

Abstract

Drug discovery and development is a long, complex, and expensive process with high failure rates. The current reliance on conventional screening methods is inefficient for testing large compound libraries. Microfluidics offers unique advantages for highly parallel and automated experimentation with low sample consumption. However, single measurement modalities have limited analytical power. Sensor fusion is an emerging approach that integrates multiple sensing principles on the same microfluidic platform, exploiting synergies between techniques to unlock the full potential of microfluidics for drug screening. This paper reviews sensor fusion strategies in microfluidic systems and discusses recent advances enabling next-generation high-throughput, high-content drug screening. We examine different integration approaches for optical, electrochemical, mechanical, thermal, and mass spectrometry sensors, highlighting key applications in target binding assays, enzymatic assays, cell-based assays, pharmacokinetic profiling, and toxicity testing. The emergence of organ-on-a-chip and body-on-a-chip devices incorporating multiple organ equivalents aided by sensor fusion heralds exciting possibilities for more predictive drug testing. We conclude with an outlook on future opportunities and challenges, underlining the vast possibilities for sensor fusion strategies to transform drug screening.

Keywords: Microfluidics, lab-on-a-chip, sensor fusion, instrumentation, high-throughput screening, drug discovery

Introduction

The intricacies of drug discovery and development pose formidable challenges, as evidenced by the staggering 90% failure rate of candidate therapeutics during clinical trials. This formidable attrition rate is predominantly ascribed to the limited predictive capabilities of traditional screening methodologies, which heavily rely on simplistic in vitro assays and animal models [1]. These conventional approaches often fall short in accurately representing the complexities of human physiology and pathology, leading to a significant translational gap between preclinical and clinical outcomes [2]. As pharmaceutical enterprises ardently seek to enhance research and development (R&D) productivity while concurrently optimizing operational efficiency, an

ORIENT review is a scientific journal publisher based in Asia, dedicated to disseminating high-quality research across various academic disciplines. With a strong commitment to fostering scholarly advancement and promoting cross-cultural understanding, ORIENT REVIEW has established itself as a reliable platform for researchers, academics, and professionals across the globe.

imperative arises for the integration of next-generation high-throughput, high-content drug screening platforms into the drug development pipeline [3].

Figure 1.



Conventional screening methods, although foundational, exhibit inherent limitations in replicating the intricate interplay of molecular, cellular, and tissue-level responses that dictate the efficacy and safety profiles of potential therapeutics [4]. The reliance on isolated in vitro assays and animal models, while providing valuable insights, fails to encapsulate the holistic spectrum of interactions that occur within the complex milieu of the human body [5]. This discrepancy contributes significantly to the subsequent failures observed during clinical trials, where the intricate dynamics of human biology manifest in ways not accurately predicted by preliminary screening efforts [6]. Furthermore, the conventional process of testing extensive libraries of compounds, often exceeding a million, is burdened by its laborious nature and exorbitant costs when conducted through standard equipment. The time-intensive and resource-demanding nature of this endeavor hampers the agility of drug development, impeding the timely identification of promising leads and hindering the progression of viable candidates through the pipeline. To address this challenge, there is a critical demand for innovative high-throughput screening platforms that amalgamate efficiency with comprehensive data generation [7].

The advent of next-generation technologies, such as organ-on-a-chip systems, advanced imaging techniques, and artificial intelligence-driven analytics, holds promise in revolutionizing drug screening paradigms. Organ-on-a-chip platforms aim to replicate the microenvironment of specific organs, enabling more accurate predictions of drug responses in a physiological context [8].

Microfluidic "lab-on-a-chip" technology has revolutionized experimentation in the life sciences by enabling precise manipulation of fluids on the sub-millimeter scale. Microfluidics provides unique advantages of reduced sample consumption, high-throughput capability, automated fluid handling, and well-controlled microenvironments—making it well-suited to drug screening [9]. However, individual sensing techniques like fluorescence, absorbance, or electrochemical detection have limited analytical power. Sensor fusion, the synergistic integration of multiple sensors and analytical modalities, can unlock the full potential of

ORIENT review is a scientific journal publisher based in Asia, dedicated to disseminating high-quality research across various academic disciplines. With a strong commitment to fostering scholarly advancement and promoting cross-cultural understanding, ORIENT REVIEW has established itself as a reliable platform for researchers, academics, and professionals across the globe.

microfluidics for multidimensional profiling of drugs with high spatiotemporal resolution [10].

This paper reviews sensor fusion strategies applied in microfluidic platforms for next-generation high-content drug screening. First, we provide a background on microfluidic tools for drug development and summarize integration approaches for different detection modes [11]. Next, we examine applications across various stages of drug screening, encompassing target-based assays, enzyme assays, cell-based assays, pharmacokinetic profiling, and toxicity testing. We also discuss the emergence of organ-on-a-chip and body-on-a-chip systems incorporating microfluidic devices with multiple organ equivalents, facilitated by sensor fusion. Finally, we consider future perspectives and challenges to be addressed [12].

Microfluidic Tools and Sensor Fusion Strategies for Drug Screening

Overview of Microfluidic Platforms: Microfluidics, a burgeoning field within the realm of fluid dynamics and engineering, revolves around the development and application of devices and techniques that enable precise control of fluids at sub-millimeter dimensions. At its core, microfluidics leverages the principles of laminar flow and diffusive mass transport to achieve well-defined spatial and temporal profiles, fostering a platform for an array of applications [13]. The integration of essential operations such as pumping, mixing, separation, reaction, and detection within a compact chip distinguishes microfluidic systems, providing a versatile and efficient means to manipulate fluids at the microscale. Central to the success of microfluidics is the material selection for device fabrication. Among the plethora of materials available, elastomers like polydimethylsiloxane (PDMS) and thermoplastics like polymethyl methacrylate (PMMA) stand out for their unique properties. PDMS, revered for its elasticity and transparency, finds extensive use in rapid prototyping owing to its facile molding capabilities. This elastomeric material not only facilitates the creation of intricate microstructures but also allows for cost-effective and swift production cycles, ideal for iterative design processes and research exploration [14].

On the other hand, thermoplastics, exemplified by PMMA, emerge as stalwarts for large-scale manufacturing in the realm of microfluidics [15]. The thermoforming characteristics of PMMA make it amenable to high-throughput production methods, ensuring the scalability necessary for industrial applications [16]. Moreover, the transparency of PMMA aids in optical analysis, a critical aspect in many microfluidic applications, such as bioassays and chemical analyses [17]. The juxtaposition of PDMS and thermoplastics exemplifies the adaptability of microfluidic materials, catering to the diverse needs of researchers and engineers across different stages of development and production. The versatility of microfluidic systems extends beyond material considerations to encompass a spectrum of functionalities. Pumping, a fundamental operation in microfluidics, involves the controlled movement of fluids within the microchannels of a device. Miniaturized pumps, often based on principles like electrokinetics or pneumatic actuation, empower precise fluid manipulation, enabling applications ranging from drug delivery systems to lab-on-a-chip platforms [18].

Microfluidics provides significant advantages over conventional methods for high-throughput experimentation , summarized in Table 1. Miniaturization to the micro-scale leads to reduced sample volumes and reagent consumption. Microfluidic designs

ORIENT review is a scientific journal publisher based in Asia, dedicated to disseminating high-quality research across various academic disciplines. With a strong commitment to fostering scholarly advancement and promoting cross-cultural understanding, ORIENT REVIEW has established itself as a reliable platform for researchers, academics, and professionals across the globe.

also enable massive parallelization with thousands of miniature reaction vessels. Automation of multiple assay steps on the same platform further allows seamless integration of various processes. Importantly, the high surface area to volume ratio at smaller dimensions translates to exquisite sensitivity [19]. Lastly, the laminar flow regime eliminates turbulence for precise spatiotemporal control. These attributes make microfluidics well-suited to drug screening [20].

Table 1. Advantages of microfluidics for high-throughput drug screening

Attribute	Technical Description
Reduced Sample Consumption	Only nanoliter to microliter volumes are required for operations, minimizing sample usage.
Massive Parallelization	Capable of conducting 10^3 to 10^4 reactions simultaneously, enabling high-throughput experimentation.
Automation	Integrates fluid handling on a single device, allowing for automated and streamlined experimental workflows.
Enhanced Sensitivity	Achieves higher sensitivity due to an increased surface area to volume ratio, optimizing detection capabilities.
Precise Control	Utilizes laminar flows to eliminate turbulence, ensuring precise control over fluid movements within the system.

Microfluidic Tools for Drug Discovery: Microfluidic devices have been applied across various stages of drug discovery and development , providing versatile tools summarized in Table 2. For primary screening of large libraries to identify bioactive compounds, droplet microfluidics compartmentalizes reactions into water-in-oil emulsions at ultrahigh throughput. Hits can then be validated by dose-response testing and secondary assays implemented in plate-based microfluidics with arrayed wells. Lead optimization relies on structure-activity relationship studies assisted by gradient generators and microfluidic parallel synthesis platforms [21].

Absorption, distribution, metabolism and excretion (ADME) profiling characterizes pharmacokinetics, commonly using organs-on-chips with endothelial-lined channels to model barriers [22]. Toxicity screening on tissue/organ chips also provides predictive capability lacking in conventional cell cultures. Moreover, multiple organ equivalents can be linked with circulating flow to emulate systemic interactions. Overall, microfluidics furnishes diverse capabilities to accelerate drug screening, albeit limited by analyte detection tools [23].

Table 2. Microfluidic devices for key drug discovery applications

Application	Microfluidic Format
Primary Screening	Utilizes Droplet Microfluidics for efficient and high-throughput screening processes.
Hit Validation	Adopts Plate-Based Microfluidics to validate and confirm potential hits identified in screening.
Lead Optimization	Employs Gradient Generators and Parallel Synthesis in microfluidic platforms for lead optimization studies.
ADME Profiling	Utilizes Organs-on-Chips and Microperfusion systems to mimic in vivo conditions for accurate ADME profiling.
Toxicity Testing	Implements Tissue/Organ Chips in microfluidics for advanced toxicity testing, providing more physiologically relevant results.
System Interactions	Utilizes Body/Multi-Organ Chips to study complex interactions between systems within the human body.

ORIENT review is a scientific journal publisher based in Asia, dedicated to disseminating high-quality research across various academic disciplines. With a strong commitment to fostering scholarly advancement and promoting cross-cultural understanding, ORIENT REVIEW has established itself as a reliable platform for researchers, academics, and professionals across the globe.

Sensor Fusion Strategies: While microfluidics facilitates a myriad of drug assay formats, most platforms rely on single detection modes like fluorescence or absorbance. However, individual techniques provide limited molecular information. Sensor fusion integrates multiple sensors to gain richer multidimensional profiles of drug candidates via different aspects , as illustrated in Figure 2. This can enhance analytical power for biological assays and expand applications [24].

Various approaches have been demonstrated for sensor fusion on microfluidic chips depending on the detection modes being combined. For macroscale sensing tools like microscopes and spectrometers, optical windows allow external coupling to on-chip processes [25]. Alternatively, complementary sensors can be integrated monolithically. In one approach, multimodal experiments occur sequentially at a common detection site. Parallel sensing is also possible with multiple dedicated readouts multiplexed spatially. Commercial macroscale detectors permit modular integration, while microfabricated sensors enable mass-producible devices [26].

Figure 2.



Importantly, sensor fusion can be achieved at different levels. With complementary fusion, sensors operate independently, and their outputs are correlated via data processing. In cooperative fusion, measurements from one detector actively guide or trigger operations of another in real-time. Lastly, in collaborative fusion, different sensing inputs are processed jointly to construct unified higher-level information. The level of fusion impinges on the degree of synergy. Collaborative schemes provide synergistic advantages from the intimate interplay between modalities [27].

Applications of Sensor Fusion Strategies for Drug Screening

In recent years, sensor fusion has emerged as a critical technological advancement, particularly in the context of microfluidic platforms for drug assays. The primary purpose of sensor fusion is to overcome the inherent limitations of individual sensing techniques, thereby enhancing measurement capabilities and providing access to information that would otherwise be inaccessible. This section delves into the application of sensor fusion in microfluidic platforms, focusing on its role in target-based binding assays, enzymatic assays, cell-based phenotypic screening, pharmacokinetic profiling, and toxicity testing. Target-based binding assays

ORIENT review is a scientific journal publisher based in Asia, dedicated to disseminating high-quality research across various academic disciplines. With a strong commitment to fostering scholarly advancement and promoting cross-cultural understanding, ORIENT REVIEW has established itself as a reliable platform for researchers, academics, and professionals across the globe.

constitute a significant area where sensor fusion in microfluidics has demonstrated notable efficacy. By integrating multiple sensing modalities, such as optical and electrochemical sensors, researchers can achieve enhanced sensitivity and selectivity in detecting molecular interactions [28]. This integration enables the simultaneous measurement of various binding events, leading to a comprehensive understanding of the assay's dynamics. This approach proves particularly valuable in drug discovery, where the identification of specific molecular interactions is crucial for the development of targeted therapies [29].

Enzymatic assays represent another domain where sensor fusion in microfluidic platforms plays a pivotal role. Combining optical, electrochemical, and acoustic sensors allows for a multifaceted analysis of enzymatic reactions. This integrated approach facilitates real-time monitoring of enzyme kinetics, substrate conversion rates, and the identification of potential inhibitors. The synergy between different sensor types in microfluidic environments enhances the precision and reliability of enzymatic assays, offering researchers a more comprehensive view of the biochemical processes under investigation [30].

Microfluidic platforms employing sensor fusion have also proven instrumental in cell-based phenotypic screening. By integrating optical sensors for imaging and impedance sensors for monitoring cellular responses, these platforms enable a holistic characterization of cellular behavior under various drug treatments. The concurrent analysis of multiple parameters provides a nuanced understanding of drug effects on cell morphology, viability, and proliferation [31]. This comprehensive profiling enhances the efficiency of drug screening processes and aids in the identification of compounds with desired therapeutic properties [32]. In the realm of pharmacokinetic profiling, sensor fusion in microfluidics contributes significantly to the analysis of drug absorption, distribution, metabolism, and excretion (ADME). By combining various sensors, such as microfabricated biosensors and mass spectrometry interfaces, these platforms enable real-time monitoring of drug concentrations and metabolic products. The integration of diverse sensing techniques enhances the accuracy of pharmacokinetic assessments, offering valuable insights into the bioavailability and clearance of drug compounds [33].

Furthermore, the application of sensor fusion in microfluidic platforms extends to toxicity testing. By incorporating sensors that can detect changes in cellular metabolic activity, membrane integrity, and oxidative stress, these platforms provide a comprehensive evaluation of potential toxic effects of drugs or chemical compounds. This integrated approach enhances the sensitivity and specificity of toxicity assessments, supporting more informed decisions in preclinical drug development.

Figure 3.



ORIENT review is a scientific journal publisher based in Asia, dedicated to disseminating high-quality research across various academic disciplines. With a strong commitment to fostering scholarly advancement and promoting cross-cultural understanding, ORIENT REVIEW has established itself as a reliable platform for researchers, academics, and professionals across the globe.

Binding Assays: Based on molecular interactions between drugs and target proteins, binding assays are the workhorses of primary screening. Label-free optical techniques like surface plasmon resonance (SPR) are commonly used. SPR measures changes in refractive index near a sensor surface where targets are immobilized when analytes bind from solution. However, the detection principle limits observing direct molecular binding events [34].

Fluorescence sensing is widely applied for biomolecular assays but lacks specificity without labels. A microfluidic platform integrated label-free SPR detection and fluorescence microscopy for RNA-small molecule binding studies. This permitted correlating molecular binding quantified by SPR with fluorescent RNA conformational changes upon target binding. The combined insights aid drug development. Similarly, SPR and fluorescence were integrated to study affinities and changes in protein conformation and dynamics.

For membranes representing cell surfaces, optical waveguide lightmode spectroscopy (OWLS) measures refractive index changes. Parallel electrical impedance spectroscopy also probes barrier integrity. An OWLS/impedance microfluidic platform enabled real-time monitoring of compound interactions with cell membrane mimics. The fusion identified permeability differences not apparent from individual readouts. By combining label-free and fluorescent techniques or different label-free modalities , microfluidics has expanded capabilities for binding assays [35].

Enzymatic Assays: Enzymatic assays characterize inhibitor efficacy and selectivity essential for drug optimization. Microfluidic platforms fuse optical absorbance or fluorescence with SPR for parallelized kinetics. SPR supplies surface binding information while absorbance tracks bulk enzymatic activity. In one study, an integrated absorbance/fluorescence/SPR chip profiled thrombin inhibitor effects. The trimodal approach determined binding kinetics, activity, and conformational thermostability.

Impedimetric biosensors also quantify enzymes electrochemically using peptides as probes. Microfluidic integration of impedance spectroscopy with SPR permitted real-time analysis of coagulation enzymes and screening of inhibitors. Overall, sensor fusion furnishes multiparametric analysis for robust enzymatic assays.

Cell-Based Phenotypic Screening: Genetic mutations and epigenetic effects mean sensing biochemical activity often poorly predicts complex phenotypic drug responses like proliferation, differentiation, and cytotoxicity. Cell-based phenotypic screening is thus critical. Microfluidic platforms sensorily fuse analytical modes to capture heterogeneous responses of cell populations in space and time [36].

For example, electrochemical impedance sensors measured barrier function of lung epithelium while transcription was quantified optically. Coupling electrical with optical systems also differentiated multidrug resistance mechanisms in cancer cells. Further addition of viability and cytotoxicity profiling better recapitulates in vivo environments for reliable screening [37].

Cardiotoxicity accounts for ~30% of drug failures in clinical trials. Contractility measurements using micro cantilevers fused with fluorescence tracked drug impacts on cardiomyocyte beating and intracellular calcium in real-time . Such multifaceted profiling improves prediction of arrhythmic liabilities. Integrated sensors decoding complex signaling activities in cells augment phenotypic screening.

ADME Profiling: Absorption, distribution, metabolism, excretion (ADME) profiling early on predicts pharmacokinetic issues to avoid costly late-stage failures.

ORIENT review is a scientific journal publisher based in Asia, dedicated to disseminating high-quality research across various academic disciplines. With a strong commitment to fostering scholarly advancement and promoting cross-cultural understanding, ORIENT REVIEW has established itself as a reliable platform for researchers, academics, and professionals across the globe.

Microfluidic gut, liver, kidney and vascular models fused with sensors delineate ADME parameters. Optical oxygen sensors quantified metabolism in gut/liver microfluidic co-cultures, correlating with permeability and absorption measured by fluorescence. This emulated first-pass metabolism. Integrated gut, liver, tumor models with embedded biosensors also assess anticancer efficacy based on metabolism at tumor sites.

Beyond optics, mass spectrometry (MS) penetration into microfluidics is limited by interfacing complexities although MS provides unmatched molecular detection. For metabolism, a cell culture/MS microfluidic platform screened environmental toxicants by profiling metabolites. Similarly, parallel cell culture reactors were interfaced to MS via rapid sampling to track vitamin antioxidant kinetics. Sensor fusion strategies thus provide multifaceted ADME evaluation [38].

Toxicity Testing: Toxic side effects are notoriously difficult to predict from in vitro assays , driving development of physiologically relevant tissue/organ chips. However, most focus narrowly on cell health indices without holistic response profiling. Advanced sensor fusion holds promise. Integrated liver chips measured tissue viability optically while hepatotoxic events were profiled with embedded electrochemical sensors. An breathing lung model coupled electrical sensors monitoring tissue integrity with mechanical readouts of respiration physiology.

Sensor fusion also aids neurotoxicity screening using brain-on-a-chip models. Microelectrode arrays measured neuronal electrical activity changes upon chemical exposure, fused with physical force monitoring. Some platforms integrate further sensory inputs like potassium ion fluctuations. Sensor fusion reveals neurotoxic mechanisms missed by individual outputs. Ultimately, complementary multidimensional signals better predict systemic toxicity.

Outlook and Future Directions

Microfluidic technologies coupled with sensor fusion strategies hold tremendous promise to overcome limitations of traditional drug screening platforms. As highlighted in this review, fusiomic devices that synergistically combine complementary detection modalities provide multiparametric profiling of drug effects with spatiotemporal resolution unmatched by conventional methods. This drives more physiologically predictive and reliable testing [39].

Expanding microfluidic sensor fusion capabilities will accelerate adoption. So far, optical modalities have dominated because instrumentation is readily available. However, portable, low-cost electrochemical/mechanical biosensors can help decentralize applications. Importantly, seamless sensor integration into microfluidic chips enables mass-manufacturing [40]. Standardizing interfaces will streamline commercial translation. Cloud-connected databases and machine learning algorithms also empower big data analytics from multidimensional profiles to improve decision making.

Body-on-a-chip systems recapitulating integrated organ physiology provide the ultimate drug screening platform. Already dual/triple organ chips fused with sensors are being deployed. Scaling up microfluidic organ models for whole-body pharmacology and toxicology testing is an active “holy grail” area. Miniaturized sensor arrays are imperative to tapping the full potential here. Implantable organs-on-chips with sensors also open possibilities for personalized medicine applications.

ORIENT review is a scientific journal publisher based in Asia, dedicated to disseminating high-quality research across various academic disciplines. With a strong commitment to fostering scholarly advancement and promoting cross-cultural understanding, ORIENT REVIEW has established itself as a reliable platform for researchers, academics, and professionals across the globe.

While microfluidic sensor fusion offers tremendous scope to transform drug screening, challenges remain. Sensing for opaque biological samples is difficult, and microsensor specificity and sensitivity tradeoffs need balancing. On-chip sensor fabrication requires multilayer lithography and cleanroom processing unfamiliar to biologists. Practical issues like sensor drift, bondingStrength and biosignal attenuation/noise during system integration must also be optimized. Nonetheless, the field is rapidly gaining momentum. Sensor fusion sits at the helm of the next wave of innovation in microfluidic technologies to radically advance drug discovery [41].

Conclusions

In this paper, we have reviewed the tremendous potential of sensor fusion strategies that integrate multiple complementary sensing modalities on microfluidic platforms to expand measurement capabilities for high-throughput, high-content drug screening. The core advantage exploits synergies between detection principles to provide multidimensional profiling of drug effects with spatiotemporal resolution not possible using single analytical techniques [42].

We examined diverse applications spanning target-binding assays, enzymatic inhibition characterization, phenotypic screening, pharmacokinetic testing and toxicity evaluation where microfluidic sensor fusion is driving more predictive, physiologically relevant drug testing to transform the drug discovery process. Significant innovations utilizing sensor fusion range from highly parallelized cell-based assays to integrated organ-on-organ and body-on-a-chip platforms that emulate interacting organ physiology.

Microfluidic sensor fusion sits at the forefront of next-generation drug screening technology development, and expanding capabilities hold vast promise for revolutionizing drug discovery. Key future directions include seamless sensor integration, standardized manufacturing, big data analytics and implantable organs-on-chips. There remain challenges in translation but the immense potential of microfluidic sensor fusion to accelerate pharmaceutical research through holistic, multidimensional profiling of drug candidates cannot be understated [43].

This technology promises to provide the predictive power lacking in traditional drug screening methods. By capturing heterogeneity of responses in space and time, microfluidic sensor fusion offers an unprecedented level of biological insight to make drug discovery exponentially more effective. The next wave of innovation in this field seeks to push boundaries of organs-on-chips towards the bold vision of a human body-on-a-chip for comprehensive drug testing.

References

[1] Y.-Y. He *et al.*, “Microfluidic-assisted assembly of fluorescent self-healing gel particles toward dual-signal sensors,” *J. Mater. Sci.*, vol. 56, no. 26, pp. 14832–14843, Sep. 2021.

[2] M. Muniswamaiah, T. Agerwala, and C. C. Tappert, “Federated query processing for big data in data science,” in *2019 IEEE International Conference on Big Data (Big Data)*, 2019, pp. 6145–6147.

[3] M. Gil, P. Velez, F. Aznar-Ballesta, A. Mesegar-Ruiz, J. Munoz-Enano, and F. Martin, “Differential microfluidic sensors based on electroinductive-wave (EIW) transmission lines,” in *2020 Fourteenth International Congress on Artificial Materials for Novel Wave Phenomena (Metamaterials)*, New York City, NY, USA, 2020.

ORIENT review is a scientific journal publisher based in Asia, dedicated to disseminating high-quality research across various academic disciplines. With a strong commitment to fostering scholarly advancement and promoting cross-cultural understanding, ORIENT REVIEW has established itself as a reliable platform for researchers, academics, and professionals across the globe.

[4] T. Kong, R. Brien, Z. Njus, U. Kalwa, and S. Pandey, "Motorized actuation system to perform droplet operations on printed plastic sheets," *Lab on a Chip*, vol. 16, no. 10, pp. 1861–1872, 2016.
[5] H. Landari, M.-A. Dussault, J. Ruel, A. Begin-Drolet, and A. Miled, "Biocompatible compact micropump with integrated unidirectional microvalves for low pressure microfluidic applications," *Sens. Actuators A Phys.*, vol. 276, pp. 246–258, Jun. 2018.
[6] M. Muniswamaiah, T. Agerwala, and C. Tappert, "Big data in cloud computing review and opportunities," *arXiv preprint arXiv:1912.10821*, 2019.
[7] B. Coelho *et al.*, "Digital microfluidics for nucleic acid amplification," *Sensors (Basel)*, vol. 17, no. 7, p. 1495, Jun. 2017.
[8] S. G. Yoon, B. J. Park, and S. T. Chang, "Highly sensitive microfluidic strain sensors with low hysteresis using a binary mixture of ionic liquid and ethylene glycol," *Sens. Actuators A Phys.*, vol. 254, pp. 1–8, Feb. 2017.
[9] X. Ding, Z. Njus, T. Kong, W. Su, C.-M. Ho, and S. Pandey, "Effective drug combination for Caenorhabditis elegans nematodes discovered by output-driven feedback system control technique," *Science advances*, vol. 3, no. 10, p. eaao1254, 2017.
[10] E. V. Moiseeva, A. A. Fletcher, and C. K. Harnett, "Thin-film electrode based droplet detection for microfluidic systems," *Sens. Actuators B Chem.*, vol. 155, no. 1, pp. 408–414, Jul. 2011.
[11] P. Dutta, "An uncertainty measure and fusion rule for conflict evidences of big data via Dempster–Shafer theory," *International Journal of Image and Data Fusion*, vol. 9, no. 2, pp. 152–169, Apr. 2018.
[12] N. Nguyen Thi Thanh, K. Nguyen Kim, S. Ngo Hong, and T. N. Lam, "Reply to legat, B.; Rocher, L. the limits of pairwise correlation to model the joint entropy. Comment on 'Nguyen Thi Thanh et al. Entropy correlation and its impacts on data aggregation in a wireless sensor network. Sensors 2018, 18, 3118,'" *Sensors (Basel)*, vol. 21, no. 11, p. 3729, May 2021.
[13] I. Kiselev *et al.*, "Erratum: Kiselev, I., et al. On the temporal stability of analyte recognition with an E-nose based on a metal oxide sensor array in practical applications. Sensors 2018, 18, 550," *Sensors (Basel)*, vol. 19, no. 16, p. 3525, Aug. 2019.
[14] T. Ye, B. Wang, P. Song, and J. Li, "Correction: Ye, T.; Et al. Automatic railway traffic object detection system using feature fusion refine neural network under shunting mode. Sensors 2018, 18, 1916," *Sensors (Basel)*, vol. 19, no. 14, p. 3044, Jul. 2019.
[15] M. Kamal and T. A. Bablu, "Machine Learning Models for Predicting Click-through Rates on social media: Factors and Performance Analysis," *IJAMCA*, vol. 12, no. 4, pp. 1–14, Apr. 2022.
[16] A. Q. Beeman, Z. L. Njus, S. Pandey, and G. L. Tylka, "Chip technologies for screening chemical and biological agents against plant-parasitic nematodes," *Phytopathology*, vol. 106, no. 12, pp. 1563–1571, 2016.
[17] J. N. Saldanha, A. Parashar, S. Pandey, and J. A. Powell-Coffman, "Multiparameter behavioral analyses provide insights to mechanisms of cyanide resistance in Caenorhabditis elegans," *toxicological sciences*, vol. 135, no. 1, pp. 156–168, 2013.

ORIENT review is a scientific journal publisher based in Asia, dedicated to disseminating high-quality research across various academic disciplines. With a strong commitment to fostering scholarly advancement and promoting cross-cultural understanding, ORIENT REVIEW has established itself as a reliable platform for researchers, academics, and professionals across the globe.

[18] Sensors Editorial Office, "Acknowledgement to reviewers of sensors in 2016," *Sensors (Basel)*, vol. 17, no. 12, p. 128, Jan. 2017.
[19] Z. Njus *et al.*, "Flexible and disposable paper-and plastic-based gel micropads for nematode handling, imaging, and chemical testing," *APL bioengineering*, vol. 1, no. 1, 2017.
[20] E. Kutafina, D. Laukamp, R. Bettermann, U. Schroeder, and S. M. Jonas, "Correction: Kutafina, E.; Laukamp, D.; Bettermann, R.; Schroeder, U.; Jonas, S.m. wearable sensors for eLearning of manual tasks: Using forearm EMG in hand hygiene training. Sensors 2016, 16, 1221," *Sensors (Basel)*, vol. 19, no. 21, p. 4792, Nov. 2019.
[21] U. Kalwa, C. Legner, E. Wlezien, G. Tylka, and S. Pandey, "New methods of removing debris and high-throughput counting of cyst nematode eggs extracted from field soil," *PLoS One*, vol. 14, no. 10, p. e0223386, 2019.
[22] N. Yahata *et al.*, "Anti-Aβ drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease," *PLoS One*, vol. 6, no. 9, p. e25788, Sep. 2011.
[23] A. M. Lerario and G. D. Hammer, "Drug repurposing using high-throughput screening identifies a promising drug combination to treat adrenocortical carcinoma," *Oncotarget*, vol. 9, no. 70, pp. 33245–33246, Sep. 2018.
[24] K. Usui *et al.*, "An ultra-rapid drug screening method for acetaminophen in blood serum based on probe electrospray ionization-tandem mass spectrometry," *J. Food Drug Anal.*, vol. 27, no. 3, pp. 786–792, Jul. 2019.
[25] A. Nassar and M. Kamal, "Ethical Dilemmas in AI-Powered Decision-Making: A Deep Dive into Big Data-Driven Ethical Considerations," *IJRAI*, vol. 11, no. 8, pp. 1–11, 2021.
[26] B. Chen, A. Parashar, and S. Pandey, "Folded floating-gate CMOS biosensor for the detection of charged biochemical molecules," *IEEE Sensors Journal*, vol. 11, no. 11, pp. 2906–2910, 2011.
[27] S. H. Au, M. D. Chamberlain, S. Mahesh, M. V. Sefton, and A. R. Wheeler, "Hepatic organoids for microfluidic drug screening," *Lab Chip*, vol. 14, no. 17, pp. 3290–3299, Sep. 2014.
[28] C. M. Legner, G. L. Tylka, and S. Pandey, "Robotic agricultural instrument for automated extraction of nematode cysts and eggs from soil to improve integrated pest management," *Scientific Reports*, vol. 11, no. 1, p. 3212, 2021.
[29] M. Zhu, "A review on recent robotic and analytic technologies in high throughput screening and synthesis for drug discovery," *Lett. Drug Des. Discov.*, vol. 12, no. 9, pp. 778–784, Sep. 2015.
[30] J. Song and A. F. Bent, "Microbial pathogens trigger host DNA double-strand breaks whose abundance is reduced by plant defense responses," *PLoS Pathog.*, vol. 10, no. 4, p. e1004030, Apr. 2014.
[31] S.-M. Yu, U.-S. Jeong, H. K. Lee, S. H. Baek, S. J. Kwon, and Y. H. Lee, "Disease occurrence in transgenic rice plant transformed with silbene synthase gene and evaluation of possible horizontal gene transfer to plant pathogens," *Sigmulbyeong Yeongu*, vol. 20, no. 3, pp. 189–195, Sep. 2014.
[32] A. Nassar and M. Kamal, "Machine Learning and Big Data Analytics for Cybersecurity Threat Detection: A Holistic Review of Techniques and Case Studies," *Intelligence and Machine Learning …*, 2021.

ORIENT review is a scientific journal publisher based in Asia, dedicated to disseminating high-quality research across various academic disciplines. With a strong commitment to fostering scholarly advancement and promoting cross-cultural understanding, ORIENT REVIEW has established itself as a reliable platform for researchers, academics, and professionals across the globe.

[33] I. Stergiopoulos and T. R. Gordon, "Cryptic fungal infections: the hidden agenda of plant pathogens," *Front. Plant Sci.*, vol. 5, p. 506, Sep. 2014.
[34] R. Na and M. Gijzen, "Escaping host immunity: New tricks for plant pathogens," *PLoS Pathog.*, vol. 12, no. 7, p. e1005631, Jul. 2016.
[35] M. F. Seidl, D. E. Cook, and B. P. H. J. Thomma, "Chromatin biology impacts adaptive evolution of filamentous plant pathogens," *PLoS Pathog.*, vol. 12, no. 11, p. e1005920, Nov. 2016.
[36] W. Colonna, B. Brehm-Stecher, K. Shetty, and A. Pometto 3rd, "Rapid screening of natural plant extracts with calcium diacetate for differential effects against foodborne pathogens and a probiotic bacterium," *Foodborne Pathog. Dis.*, vol. 14, no. 12, pp. 719–727, Dec. 2017.
[37] T. Kong, N. Backes, U. Kalwa, C. Legner, G. J. Phillips, and S. Pandey, "Adhesive tape microfluidics with an autofocusing module that incorporates CRISPR interference: applications to long-term bacterial antibiotic studies," *ACS sensors*, vol. 4, no. 10, pp. 2638–2645, 2019.
[38] F. Bouchama and M. Kamal, "Enhancing Cyber Threat Detection through Machine Learning-Based Behavioral Modeling of Network Traffic Patterns," *IJBIBDA*, vol. 4, no. 9, pp. 1–9, Sep. 2021.
[39] F. A. M. Tuyttens, C. F. M. Molento, and S. Benaissa, "Twelve threats of Precision Livestock Farming (PLF) for animal welfare," *Front. Vet. Sci.*, vol. 9, p. 889623, May 2022.
[40] W. Maohua, "Possible adoption of precision agriculture for developing countries at the threshold of the new millennium," *Comput. Electron. Agric.*, vol. 30, no. 1, pp. 45–50, Feb. 2001.
[41] C. K. Choi and H. H. Yoo, "Precision fault diagnosis procedure for a structural system having a defect employing Hidden Markov Models," *Int. J. Precis. Eng. Manuf.*, vol. 15, no. 8, pp. 1667–1673, Aug. 2014.
[42] R. Finger, S. M. Swinton, and N. El Benni, "Precision farming at the nexus of agricultural production and the environment," *Annual Review of*, 2019.
[43] J. A. Carr, R. Lycke, A. Parashar, and S. Pandey, "Unidirectional, electrotactic-response valve for Caenorhabditis elegans in microfluidic devices," *Applied Physics Letters*, vol. 98, no. 14, 2011.